By a GenomeWeb staff reporter
NEW YORK (GenomeWeb News) – Fluidigm reported after the close of the market Tuesday that its third-quarter revenues increased 25 percent to $10.6 million from $8.5 million year over year, matching Wall Street expectations.
Registering provides access to this and other free content.
Already have an account?Login Now.
In Science this week: factors influencing retrotransposon integration sites, and more.
A bioethicist argues for the responsible use of germline gene editing.
Some breweries are using DNA-based testing to determine whether unwanted bacteria are affecting their beers, The Verge reports.
Standardized N-of-1 trials will be needed to test out personalized medicines, writes Nicholas Schork from the J. Craig Venter Institute at Nature.